Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.050
-0.010-0.10%
Volume:2.76M
Turnover:27.59M
Market Cap:10.57B
PE:-23.24
High:10.560
Open:10.560
Low:9.760
Close:10.060
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:0.79
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.432
ROE:-28.59%
ROA:-19.64%
PB:3.98
PE(LYR):-23.24
PS:9554.08

Loading ...

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

Reuters
·
Yesterday

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Stock News
·
Sep 08

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS
·
Sep 08

Ascletis Pharma Joins Two Chinese Stock Connect Programs

MT Newswires Live
·
Sep 07

Ascletis to Join Shanghai- and Shenzhen-Hong Kong Stock Connect, Unlocking Mainland Investor Access

Bulletin Express
·
Sep 07

Ascletis Announces Inclusion in the Hong Kong Stock Connect List Under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

THOMSON REUTERS
·
Sep 07

歌礼制药-B股价早盘攀升逾8%,重磅减肥药全球III期试验迎来关键里程碑

Deep News
·
Sep 02

Sweden's Klaria Net Loss Narrows on Lower R&D Expenses

Reuters
·
Sep 01

China's United Laboratories Half-Year Profit Drops 82%

Reuters
·
Aug 31

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 31

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31

Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy

THOMSON REUTERS
·
Aug 31

Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million

Reuters
·
Aug 31

Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million

THOMSON REUTERS
·
Aug 31

Ascletis Pharma Starts Phase III Trial of Weight-Loss Drug; Shares Plummet 5%

MT Newswires Live
·
Aug 31

Ascletis Advances ASC30: First Patient Dosed in 4,600-Subject Global Phase III Trials for Oral GLP-1 Weight-Loss Therapy

Bulletin Express
·
Aug 30

Ascletis Announces First Participant Dosed in a Global Phase Iii Clinical Program of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist Asc30 for Chronic Weight Management

THOMSON REUTERS
·
Aug 30

Ascletis Pharma - Topline Phase Iii Data Expected Q3 2028; FDA Nda by End 2028; Ema Maa Early 2029

THOMSON REUTERS
·
Aug 30

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses

Reuters
·
Aug 24